Page 23 - Cardiac Nursing

6
/
/
d
6
6
/
09
09
30
30
/
i.
i.
q
vii
vii
i.
x
x
d
q
q
x
1:
i A
i A
p
e
xvi
xvi
ta
r
r
p
p
ta
13
PM
PM
1:
13
13
g
g
e
Pa
Pa
g
LWB
LWBK340-F0-FM_
K34
M_
0-F
LWB K34 0-F M_ p p ppi-xviii.qxd 6/30/09 1:13 PM Page xvii Aptara a a
i-x
i-x
Contents xvii
Diagnostic Testing for Valvular Heart Disease 707 Diabetes Mellitus 759
Mitral Stenosis 707 Body Weight 761
Tricuspid Valve Disease 710 Reproductive Hormones 762
Prosthetic Valves 711 Folate and Homocysteine 763
Mitral Insufficiency 713 Antioxidants 763
Mitral Valve Prolapse 715 Conclusions 764
Aortic Stenosis 717
Aortic Insufficiency 719 CHAPTER 33
CHAPTE R 30 Psychosocial Risk Factors: Assessment and
Management Interventions 769
Pericardial, Myocardial, and Endocardial Simone K. Madan • Erika S. Sivarajan
Disease 722
Froelicher
Margaret M. McNeill
Psychosocial Risk Factors for CHD 769
Pericardial Disease 722 Pathophysiological Mechanisms for Psychosocial Risk Factors
Cardiomyopathies 728 and CHD 771
Endocardial Disease 733 Assessment of Psychosocial Risk Factors Related to CHD 772
C HAPTE R 31 Psychosocial Interventions in CHD 775
Pharmacological Interventions for Psychosocial Risk Factors in
CHD 778
Adult Congenital Heart Disease 738 Summary 779
Philip Moons • Mary M. Canobbio C HAPTER 34
Incidence and Prevalence 738
Categorization of Congenital Heart Defects 738 Smoking Cessation and Relapse
Acyanotic Heart Defects with Left-to-Right Shunt 738 Prevention 783
Acyanotic Heart Defects with Left Heart
Obstruction 742 Min Sohn • Mark Hawk • Kirsten Martin •
Acyanotic Heart Defects with Right Heart Obstruction 744 Erika S. Sivarajan Froelicher
Malposition and Malconnection 745
Harmful Effects of Smoking 783
Cyanotic Heart Defects with Diminished Pulmonary
Benefits of Smoking Cessation 784
Blood Flow 746
Theoretical Framework for Smoking Cessation 784
Cyanotic Heart Defects with Increased Pulmonary Blood Flow 747
Smoking Cessation Interventions in the CHD Population 784
Cyanotic Heart Defects with Common Mixing 748
General Trends in Smoking Cessation Interventions 785
Eisenmenger Reaction 750
Treating Tobacco Use and Dependence: Clinical Practice
Guideline 785
Special Areas on which to Focus 793
V Summary 795
PA R T CH A PTER 35
Health Promotion and Disease
Prevention 753 Hypertension 799
Cheryl R. Dennison • Nancy Houston Miller •
Susanna G. Cunningham
CH A PTE R 32 Evidence for Management 799
Management of HTN 804
Coronary Heart Disease Risk Factors 753
Summary 817
M. Kaye Kramer • Katherine M. Newton • CH A PTER 36
Erika S. Sivarajan Froelicher
Demographic Characteristics 753 Lipid Management and Cardiovascular
Family History of Cardiovascular Disease 755 Disease 823
Cigarette Smoking 755
Kathleen A. Berra • Joan M. Fair
Hypertension 756
Serum Lipids and Lipoproteins 756 Blood Lipids: Structure and Functions 823
Physical Activity 758 Lipid Metabolism and Transport 825